



# DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

## Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant Staphylococcus aureus

The Harvard community has made this article openly available.  
[Please share](#) how this access benefits you. Your story matters.

<b>Citation</b>	Rajamuthiah, Rajmohan, Beth Burgwyn Fuchs, Elamparithi Jayamani, Younghoon Kim, Jonah Larkins-Ford, Annie Conery, Frederick M. Ausubel, and Eleftherios Mylonakis. 2014. "Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant Staphylococcus aureus." PLoS ONE 9 (2): e89189. doi:10.1371/journal.pone.0089189. <a href="http://dx.doi.org/10.1371/journal.pone.0089189">http://dx.doi.org/10.1371/journal.pone.0089189</a> .
<b>Published Version</b>	<a href="https://doi.org/10.1371/journal.pone.0089189">doi:10.1371/journal.pone.0089189</a>
<b>Accessed</b>	April 17, 2018 4:47:05 PM EDT
<b>Citable Link</b>	<a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879738">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879738</a>
<b>Terms of Use</b>	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>

*(Article begins on next page)*

# Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant *Staphylococcus aureus*

Rajmohan Rajamuthiah<sup>1,2</sup>, Beth Burgwyn Fuchs<sup>1,2</sup>, Elamparathi Jayamani<sup>1,2</sup>, Younghoon Kim<sup>3</sup>, Jonah Larkins-Ford<sup>2</sup>, Annie Conery<sup>2</sup>, Frederick M. Ausubel<sup>2</sup>, Eleftherios Mylonakis<sup>1,2\*</sup>

**1** Division of Infectious Diseases, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America, **2** Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, **3** Department of Animal Science, Chonbuk National University, Jeonju, Republic of Korea

## Abstract

*Staphylococcus aureus*, the leading cause of hospital-acquired infections in the United States, is also pathogenic to the model nematode *Caenorhabditis elegans*. The *C. elegans*-*S. aureus* infection model was previously carried out on solid agar plates where the bacterivorous *C. elegans* feeds on a lawn of *S. aureus*. However, agar-based assays are not amenable to large scale screens for antibacterial compounds. We have developed a high throughput liquid screening assay that uses robotic instrumentation to dispense a precise amount of methicillin resistant *S. aureus* (MRSA) and worms in 384-well assay plates, followed by automated microscopy and image analysis. In validation of the liquid assay, an MRSA cell wall defective mutant, MW2 $\Delta$ tarO, which is attenuated for killing in the agar-based assay, was found to be less virulent in the liquid assay. This robust assay with a Z'-factor consistently greater than 0.5 was utilized to screen the Biomol 4 compound library consisting of 640 small molecules with well characterized bioactivities. As proof of principle, 27 of the 30 clinically used antibiotics present in the library conferred increased *C. elegans* survival and were identified as hits in the screen. Surprisingly, the antihelminthic drug closantel was also identified as a hit in the screen. In further studies, we confirmed the anti-staphylococcal activity of closantel against vancomycin-resistant *S. aureus* isolates and other Gram-positive bacteria. The liquid *C. elegans* – *S. aureus* assay described here allows screening for anti-staphylococcal compounds that are not toxic to the host.

**Citation:** Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, et al. (2014) Whole Animal Automated Platform for Drug Discovery against Multi-Drug Resistant *Staphylococcus aureus*. PLoS ONE 9(2): e89189. doi:10.1371/journal.pone.0089189

**Editor:** Gunnar F. Kaufmann, The Scripps Research Institute and Sorrento Therapeutics, Inc., United States of America

**Received:** October 5, 2013; **Accepted:** January 15, 2014; **Published:** February 19, 2014

**Copyright:** © 2014 Rajamuthiah et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by National Institutes of Health grant P01 AI083214 to EM and FA and grant U54 AI057159 to NERCE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: Eleftherios\_Mylonakis@Brown.edu

## Introduction

*Staphylococcus aureus* is a human commensal that is a leading cause of hospital and community-acquired infections [1,2], including bacteremia and sepsis [3,4]. Staphylococci possess a wide spectrum of virulence factors and have developed many strategies to bypass host defense mechanisms [5,6]. In addition, the rapid development of *S. aureus* strains resistant to  $\beta$ -lactam antibiotics such as methicillin (MRSA) present challenges in the treatment of staphylococcal infections. The CDC estimates that in 2011, MRSA was responsible for 80,461 life-threatening infections in the United States alone [7]. In fact, the number of yearly deaths from MRSA infection has surpassed that of AIDS [7]. These statistics underscore the urgent need for novel anti-infectives effective against *S. aureus*.

Traditional methods of antimicrobial drug discovery have usually involved *in vitro* screening for antimicrobial activity and then further *in vitro/in vivo* testing of the hits for toxicity followed by Structure Activity Relationships (SAR) analysis [8]. One shortcoming of this method of antibiotic discovery is that many compounds that are lethal to bacteria are also toxic to humans. We present here a model using a whole animal host *Caenorhabditis elegans* for antimicrobial screening that enables simultaneous

assessment of the toxicity of the compound to the host as well as the efficacy of the compound against the pathogen. In addition to conventional antibiotics that affect bacterial growth or viability, our whole animal screening model allows the identification of immunomodulatory compounds and compounds that affect pathogen virulence.

The free living nematode *C. elegans* has recently become a popular model organism for studying pathogenesis of many microbes [9,10], including *S. aureus* [11,12]. *C. elegans* growing on a lawn of *S. aureus* die within five days, whereas nematodes feeding on non-pathogenic *E. coli*, the normal laboratory food source, or non-pathogenic *Bacillus subtilis*, live approximately 14 days [11,13]. Importantly, key virulence factors that are important for staphylococcal pathogenesis in the nematode model are also involved in pathogenesis in humans [11]. *C. elegans* are relatively inexpensive to maintain and their use does not raise ethical concerns related to the use of mammals in biological research. A main objective of this study was to develop a *C. elegans*-MRSA liquid infection assay for automated, high throughput screening of small molecule libraries for antibacterial compounds. The screening methodology was subsequently used to identify antimicrobials in the Biomol 4 library of FDA-approved drugs that promote survival of infected worms. Proof of principle is

demonstrated by the fact that out of the 30 clinically used antibiotics represented in the library, 27 were identified as hits in the screen (Tables 1 and 2). The method described here can be applied to assays with other pathogens with only slight modifications. Our results confirm the utility of *C. elegans* as a screening platform for antimicrobial drug discovery.

## Materials and Methods

### Bacterial and Nematode Strains

The *S. aureus* methicillin resistant strain MW2 BAA-1707 (ATCC, Manassas, VA, USA) was used throughout this study. It is a community-acquired (CA-MRSA) strain, SCC<sub>mec</sub> Type IV, Pantone-Valentine Leucocidin (PVL)-Positive that was isolated in 1998 from a female patient in North Dakota (USA) [14]. The *S. aureus* strain VRS1 carries a plasmid encoding the *vanA* gene that confers resistance to vancomycin [15]. The cell wall defective strain MW2Δ*tarO* expresses an inactive, truncated variant of TarO containing only 80 aa [16]. Bacteria were grown at 37°C in tryptic soy broth (TSB, Becton Dickinson and Company, NJ, USA).

The *C. elegans* *glp-4(bn2);sek-1(km4)* double mutant strain was used throughout this study. Nematodes were maintained at 15°C on a lawn of *E. coli* strain HB101 on 10 cm plates [17]. The *glp-4(bn2)* mutation renders the strain incapable of producing progeny at 25°C [18] and the *sek-1(km4)* mutation enhances sensitivity to various pathogens [19], reducing assay time.

### Compound Library

The Biomol 4 library (<http://www.enzolifesciences.com/>) is a collection of 640 FDA-approved drugs that were chosen for their chemical and pharmacological diversity. The library was obtained from the Institute of Chemistry and Cell Biology (ICCB) at Harvard Medical School in 384-well plates. For all plates, 0.1 μl of each of the 2 mg/ml compound stocks in DMSO was pin transferred to separate wells. The compounds were screened at a final compound concentration of 2.86 μg/ml.

### Z'-factor

Z'-factor is a measure of the quality of the HTS assay pipeline and it is calculated from the positive and negative control data [20].  $Z' \text{-factor} = 1 - ((3\sigma_p + 3\sigma_n) / |\mu_p - \mu_n|)$  where  $\sigma_p$  and  $\sigma_n$  are the standard deviations of the positive and negative controls respectively and  $\mu_p$  and  $\mu_n$  are the means of the positive and negative controls respectively. A Z'-factor >0.5 indicates a robust assay. For experiments used to determine the Z'-factor of the assay, 1%

**Table 2.** Antibiotic hits and their corresponding Z scores in the *C. elegans*-MRSA infection assay.

Name	Z score
Cefoperazone acid [39]	3.56
Cefotaxime acid [40]	6.44
Clinafloxacin HCl [41]	7.11
Clindamycin HCl [42]	23.82
Doxycycline HCl [43]	5.43
Enoxacin [44]	2.85
Enrofloxacin [45]	7.12
Fleroxacin [46]	3.51
Gatifloxacin [47]	6.73
Levofloxacin HCl [48]	7.16
Lincomycin [49]	21.13
Linezolid [42]	8.18
Lomefloxacin HCl [50]	7.11
Minocycline HCl [51]	5.18
Nadifloxacin [52]	6.68
Novobiocin Na [53]	30.07
Ofloxacin [54]	7.16
Pazufloxacin [55]	7.04
Pefloxacin mesylate [56]	7.16
Rifampicin [42]	29.85
Rifamycin sv [57]	7.12
Roxithromycin [58]	6.44
Rufloxacin [59]	2.01
Sarafloxacin HCl [54]	6.66
Sparfloxacin [60]	6.57
Tosufloxacin [61]	6.73
Troleandomycin [62]	23.10

doi:10.1371/journal.pone.0089189.t002

dimethyl sulfoxide (DMSO) was the negative control and vancomycin hydrochloride (Sigma Aldrich, MO, USA) dissolved in DMSO at a final concentration of 10 μg/ml was the positive control.


### Infection Assay for Compound Screen

*S. aureus* MW2 was grown overnight in TSB under aerobic conditions with agitation at 37°C. To simulate the growth environment of *S. aureus* in a wound abscess, the aerobic culture was shifted to anaerobic growth conditions the next day by seeding a 10 ml TSB culture tube with 100 μl of the aerobic culture, sealing the tube in an air-tight manner, and incubating overnight without agitation at 37°C. It has been shown that anaerobically grown *S. aureus* exhibits a different pattern of virulence gene expression than aerobically grown cultures [21]. Two thousand *glp-4(bn2);sek-1(km4)* worms at the L1 stage were grown at 15°C on SK agar plates with HB101 as the food source for four days until the worms reached the gravid adult stage. Embryos were harvested from adult worms according to a previously described method [22] and the eggs were hatched by incubation in M9 buffer at 15°C for two days. Approximately 4,500 L1 hatchlings were grown on SK-HB101 agar plates for 52 hours at the restrictive temperature of 25°C until animals were sterile young

**Table 1.** Classes of compounds from the Biomol 4 library that promote survival of nematodes infected with MRSA.

Category	Number of hits
Antibiotics	27*
Anticancer	10
Antiviral	1
Antifungal	1
Antiarthritic drug	1
Non-steroidal estrogen	1
Anthelminth	1
<b>Total</b>	<b>42</b> (6.6% hit rate)

\*- Z scores >3 for 25 antibiotic hits and 2 < Z score < 3 for 2 antibiotic hits.  
doi:10.1371/journal.pone.0089189.t001

**High Throughput Screening Scheme**


**Figure 1. Flowchart representing the time line and work flow of the *C. elegans*-MRSA high throughput screening assay.**  
doi:10.1371/journal.pone.0089189.g001

adults. The worms were harvested by gently washing them off the plates with M9 buffer.

The HTS assay was performed using 384-well plates (Corning no. 3712). A Union Biometrica Complex Object Parametric Analyzer and Sorter (COPASBioSort) was used to transfer 15 adult worms to each well of the assay plate. The total volume in

each well was 70  $\mu$ l with the final composition being 70% M9 buffer, 19% Sheath solution (Union Biometrica Part no. 300-5101-000), 10% TSB, and 1% DMSO or compounds dissolved in DMSO. The bacterial concentration was adjusted to a final OD<sub>600</sub> of 0.04. After 5 days of incubation in a humidified chamber at 25°C, the bacteria and other debris were washed from the wells

## Image Analysis of High Content Data




**Figure 2. Worm survival quantification using CellProfiler.** Worms in 384-well plates were incubated with Sytox Orange, which specifically stains dead worms. The results of several processing steps using CellProfiler are shown. The total area of fluorescent and bright field worms are measured and worm survival in each well is calculated as a percentage. **Top row:** Raw fluorescent Sytox Orange and bright field images of an untreated and an antibiotic-treated well. **Middle row:** Correction for uneven illumination of the bright field images. Cropping of Sytox images so that total fluorescence measurements are only made within worm areas determined by the bright field images. **Bottom row:** Thresholding, identifying worms and filtering for object size.  
doi:10.1371/journal.pone.0089189.g002

with a microplate washer, leaving 10  $\mu$ l of assay volume with worms following the final aspiration step. Finally, 60  $\mu$ l of 0.9  $\mu$ M Sytox Orange in M9 was dispensed into each well for a final Sytox concentration of 0.7  $\mu$ M. The plates were incubated overnight at 25°C in a humidified chamber. The plates were imaged the next day using an Image Xpress Micro automated microscope (Molecular Devices), capturing both transmitted light and TRITC (535 nm excitation, 610 nm emission) fluorescent images with a 2X objective.

#### Worm Survival Quantification using CellProfiler and Hit Identification

The transmitted and fluorescent images of worms in 384 well plates obtained using the Image Express Micro microscope were processed with the open source image analysis software CellProfiler (<http://www.cellprofiler.org/>) using a pipeline of image processing and analysis modules as described previously [23,24]. The ratio of Sytox worm area to bright field worm area, and the resultant percentage survival data, is calculated by the software for each well of the assay plates. In order to identify the hits, the Z score was calculated from the ratio data. The Z score is defined as

## Optimization of MW2 Bacterial Concentration for the Liquid Assay



**Figure 3. Optimization of starting bacterial concentration used in the infection assay.** Worms display a dose dependent susceptibility to the *S. aureus* MW2 starting inoculum.  
doi:10.1371/journal.pone.0089189.g003

the number of standard deviations an observation is separated from the mean;  $Z = (x - \mu) / \sigma$  where  $x$  is the raw sample score,  $\mu$  is the mean of the population and  $\sigma$  is the standard deviation of the population. Samples with  $Z > 2\sigma$  were considered as hits.

### Antimicrobial Activity Testing

Compounds (10 mg/ml stock solution in DMSO) were tested for antimicrobial activity by broth microdilution, adapted from established protocols [25]. The assay was done in triplicate in 384-well plates. The total volume in each well was 40  $\mu$ l with the final composition being 50% M9 buffer, 50% TSB. Two-fold serial dilutions were carried out to get compounds in the concentration range 0.78–50  $\mu$ g/ml. The bacterial concentration was adjusted to an initial OD<sub>600</sub> of 0.03. After overnight incubation at 37°C, the absorbance was measured to determine antimicrobial activity.

## Results and Discussion

### MRSA-*C. elegans* Liquid Killing Assay for High Throughput Screening


*C. elegans-S. aureus* infection models have been used in several studies investigating staphylococcal virulence and pathogenesis, as well as in screens for compounds with antimicrobial activity [11,12,26–30]. Previous work has demonstrated that *S. aureus* is pathogenic to *C. elegans* and staphylococcal infection in nematodes is characterized by bacterial accumulation that causes intestinal distension [31]. In the original agar-based assay, nematodes were fed on a lawn of pathogenic bacteria to establish the infection and at an appropriate time point, worm survival was assayed by gently probing the nematodes with a platinum loop to determine whether they moved in response to touch. While this method might be suitable for small scale screens, a less laborious approach utilizing automation is necessary for high throughput, large scale screening.

A liquid-based screening assay was previously established for *C. elegans* infected with *Enterococcus faecalis* [24,32]. However, adaptations had to be made for the *C. elegans* – MRSA assay. Specifically, in the *C. elegans-E. faecalis* HTS assay, larval stage L4 worms were


pre-infected with the pathogen prior to sorting. However, using instrumentation to sort and dispense MRSA-infected worms is not feasible because the robotic equipment cannot be efficiently decontaminated after each use. To circumvent this problem, the effectiveness of a co-infection assay, which involved sorting and dispensing the worms in the assay wells and then inoculating the wells with bacteria, was assessed (Fig. 1). Since a standard *C. elegans-S. aureus* infection experiment on solid agar is carried out for up to 5 days or longer [11], the liquid assay was carried out for a similar duration. At the end of the assay, the wells were washed to remove the bacteria and worms were stained with Sytox Orange, which preferentially stains dead worms. The assay plates were imaged with an ImageXpress microscope, capturing both transmitted light and TRITC (535 nm excitation, 610 nm emission) fluorescent images with a 2X objective. The use of a 2X objective allows capturing the area of an entire well within one image. The image data were analysed with CellProfiler image analysis software to calculate worm survival based on fluorescence and transmitted light images (Fig. 2). A similar liquid-based screening assay has recently been described for a *C. elegans-P. aeruginosa* pathogenesis model [33].

The liquid *C. elegans-S. aureus* assay was first optimized by testing several concentrations of the MRSA strain MW2 with the starting concentration ranging from an OD<sub>600</sub> of 0.02 to 0.05. As a negative control, the non-pathogenic *E. coli* strain OP50 was added to the worms at the same concentration while keeping other conditions unchanged. More than 90% of the worms treated with OP50 survived after 5 days of co-infection for initial OD<sub>600</sub> < 0.04, but survival dropped to 73% when the starting OD<sub>600</sub> > 0.04 (Fig. 3). It is possible that higher bacterial loads might kill worms by suffocation, especially if the bacteria grow at a rate faster than their consumption by the worms. Though *C. elegans* is able to withstand low ambient oxygen levels, prolonged anoxia increases mortality [34]. In contrast to worms exposed to *E. coli*, the survival rate of worms exposed to *S. aureus* MW2 decreased to as low as 5% with an initial OD<sub>600</sub> of 0.05 (Fig. 3), confirming that *S. aureus* is also capable of killing *C. elegans* in liquid media, similar to assays

A



B




**Figure 4. *C. elegans*-MRSA liquid infection assay in 384-well plates.** **A)** Assay plates were co-inoculated with nematodes, bacteria and either DMSO (negative control) or vancomycin (10 µg/ml, positive control). The plates were incubated at 25°C for 5 days, washed to remove residual bacteria and imaged. The tiled image was constructed from TRITC fluorescent images of each well from a 384-well plate. **B)** Worm survival was significantly enhanced in wells treated with vancomycin. doi:10.1371/journal.pone.0089189.g004

performed on solid agar plates. Given these results, an OD<sub>600</sub> of 0.04, was deemed suitable for the infection assay as non-pathogenic *E. coli* OP50 does not cause killing at this bacterial concentration, whereas MW2 causes robust killing.

#### Evaluation of the Co-infection Assay

In order to determine the reproducibility and reliability of the liquid infection assay, the Z'-factor, a standard measure of robustness of high throughput assays, was determined. The Z'-

factor was calculated from CellProfiler-generated percentage survival data from images of wells treated with DMSO (negative control) and vancomycin (positive control) (Figure 4A). The Z'-factor of the screening assay is 0.77 (Fig. 4B), which indicates a very robust assay that is suitable for large scale screening.



**Figure 5. A cell wall defective MRSA strain displays attenuated killing of *C. elegans* in the liquid infection assay.** Survival of worms infected with either MW2 or MW2 $\Delta tarO$  was assayed under the same assay conditions. MW2 $\Delta tarO$  was significantly attenuated in killing compared to the wild type MW2 strain in the DMSO wells. Error bars represent standard error.  
doi:10.1371/journal.pone.0089189.g005

#### Testing a Cell Wall Defective Strain in the Liquid Infection Assay


In order to further confirm that the liquid killing assay behaves similarly to the standard agar killing assay, we compared nematode killing mediated by MW2 and MW2 $\Delta tarO$ , a mutant defective in wall teichoic acid (WTA) biosynthesis [35]. The

mutant strain defective in WTA biosynthesis is modestly attenuated compared to a wild type strain in killing *C. elegans* on agar plates [36]. In the liquid assay, worms infected with MW2 $\Delta tarO$  had a higher mean survival rate of 42.8% as compared to 9.6% for worms infected with wild type MW2 (Fig. 5), demonstrating that a previously tested mutant that was less virulent in an agar-based assay is also less virulent in the liquid assay. Although the WTA mutant strain is attenuated in both the agar and liquid-based assays, the degree of attenuation of MW2 $\Delta tarO$  is greater in liquid than on agar. This suggests that the mechanism by which MW2 kills *C. elegans* in liquid may be different than on solid and that WTA biosynthesis may play a greater role in liquid killing than in the agar-based infection assay.

#### Identification of Antibiotic Compounds from the Screen

Using the optimized liquid screening assay, a pilot screen was conducted with the Biomol 4 compound library consisting of 640 compounds representing several classes of drugs. These compounds include 30 clinically used antibiotics with *in vitro* activity against MRSA [37–62]. Based on the Z score threshold of 3, there was a total of 40 hits, 25 of which were known antibiotics (Tables 1 and 2). Antibiotics such as clindamycin, lincomycin, novobiocin, rifampicin and troleandomycin had Z scores greater than 20 suggesting that they are very strong hits. When the Z score threshold was lowered to 2, two more antibiotics, enoxacin and rifloxacin, were identified as hits. Both enoxacin and rifloxacin have *in vitro* activity against MRSA [44,59], suggesting that the Z score threshold of 2 may be appropriate in identifying hits for this screen. In Figure 6, we present an example assay plate where wells with a Z score greater than 2 have been highlighted in white squares.


Interestingly, the Biomol 4 library includes three different formulations of clindamycin, as a hydrochloride, phosphate and




**Figure 6. Sytox staining of assay plate.** Tiled image of an example assay plate constructed from Sytox fluorescence images. White boxes indicate compounds that enhanced survival of infected worms with Z score greater than 2, the red box indicates DMSO control wells, and the green box indicates vancomycin positive control wells.  
doi:10.1371/journal.pone.0089189.g006



A



B



**Figure 7. Closantel has a low *in vitro* MIC against VRSA. A)** Structure of closantel. **B)** *In vitro* antimicrobial activity of closantel was compared with vancomycin against the vancomycin resistant strain VRS1. doi:10.1371/journal.pone.0089189.g007

palmitate, but only clindamycin hydrochloride was identified as a hit. Clindamycin hydrochloride is orally administered in capsules whereas the palmitate version is present in oral suspensions and clindamycin phosphate is topically administered. Among the three versions, clindamycin hydrochloride probably had the highest solubility, thereby accounting for its effectiveness in the assay.

Thus, the particular formulation of an antibiotic might affect its activity in the assay.

The assay failed to detect three clinical antibiotics, gentamicin, ciprofloxacin and trimethoprim. Trimethoprim is clinically effective on *S. aureus* only in combination with sulfamethoxazole [37]. Gentamicin and ciprofloxacin are mostly active against Gram-negative bacteria and it is clinically recommended to use these

**Table 3. *In vitro* antimicrobial activity of closantel.**

MIC (µg/ml)						
Compound	<i>E. coli</i> (OP50)	<i>B. subtilis</i> (PY79)	MRSA (MW2)	VRSA (VRS1)	<i>E. faecalis</i> (MMH594)	<i>E. faecium</i> (E007)
Vancomycin	>50	<0.78	3.12	>50	6.25	1.56
Closantel	>50	<0.78	<0.78	<0.78	<0.78	<0.78

doi:10.1371/journal.pone.0089189.t003

antibiotics in combination with vancomycin or rifampicin for treating MRSA infections [63]. Also, we screened all compounds at a relatively low concentration of 2.86  $\mu\text{g}/\text{ml}$ , which might not be sufficient for *in vivo* activity since it is likely that compounds may degrade and worms may metabolize and inactivate some of the compounds during the treatment period. Performing the assay at higher compound concentrations might enable a higher rate of detection but it might also increase the possibility that a potential hit might be missed due to toxicity to worms. Ideally, the screen would be performed at varying compound concentrations, which is not practical when screening large chemical libraries.

### Closantel is Active against Vancomycin Resistant Staphylococci

One finding from this screen that drew our attention is that the anthelmintic drug closantel (Fig. 7A) was able to prolong the survival of nematodes in the liquid assay. Closantel is marketed as a veterinary anthelmintic drug that is effective against several species of nematodes [64,65]. Closantel is in the salicylanilide class of drugs and although it has not been well studied, its anthelmintic activity is thought to be as an uncoupler of oxidative phosphorylation [66]. One might have expected that even if closantel does have antibacterial activity, this compound would not have been identified as a hit in our screen because of its toxicity to helminths. However, closantel was identified as a hit with a relatively high Z score of 7.16.

We tested the *in vitro* activity of closantel against other bacteria such as *E. coli*, *B. subtilis*, *E. faecalis* and *Enterococcus faecium* and found that indeed, it has a very low MIC with all Gram-positive bacterial species tested (Table 3), similar to the findings in an earlier study [67]. We found that this compound is also active against another antibiotic-resistant *S. aureus* isolate, the VRSA strain VRS1, with an MIC of at most 0.78  $\mu\text{g}/\text{ml}$  (Table 3, Fig. 7B). In comparison, the MIC of oxacillin or vancomycin for the same strain was  $>256 \mu\text{g}/\text{ml}$  [15]. In order to test whether closantel extends the lifespan of *C. elegans* exposed to MRSA by inhibiting the growth of MRSA in the screening assay, we measured the antibacterial activity of closantel on MRSA in the assay wells in the presence of *C. elegans*. We measured the  $\text{OD}_{600}$  of the wells with or without closantel at the start and end of an infection assay. Unexpectedly, we found that the  $\text{OD}_{600}$  of MRSA in wells containing closantel was on average similar to wells without closantel at both the beginning of the assay ( $\text{OD}_{600} \sim 0.03$ ) and at the end of the assay ( $\text{OD}_{600} \sim 0.8$ ) (data not shown). Our data suggest that closantel is not affecting the growth of MRSA in the assay despite the fact that closantel has a low MIC ( $\sim 0.78 \mu\text{g}/\text{ml}$ ).

Intriguingly, Hlasta et al. [67] showed that closantel inhibits two-component signaling (TCS) regulators in *B. subtilis*. TCS regulators are conserved bacterial transcriptional regulators that control a wide variety of processes in bacteria, such as virulence, antibiotic resistance, and ability to adapt to the external environment [68–70]. This suggests that the mechanism by which closantel may promote longer lifespan in *C. elegans* exposed to pathogen is by targeting master *S. aureus* transcriptional regulators. Reasoning that TCS mutants corresponding to closantel targets

may be more susceptible to closantel, we tested the activity of closantel on several *S. aureus* strains containing mutations in the VraR-VraS TCS, a system important in promoting antibiotic resistance, and GraR-GraS, a system important for virulence. However, closantel inhibited the growth of the mutant strains to a similar degree as the wild type strain (data not shown). Since it is difficult to interpret these negative results, additional studies are required to determine whether TCS of *S. aureus* is a potential target of closantel. The TCS system, in general, may present an attractive target for antimicrobial therapy as suggested by previous studies [70–72].

In addition to the possibility that closantel targets bacterial virulence, it is also possible that closantel could accumulate to low levels in *C. elegans* cells and affect its biology, although it is clearly not toxic to *C. elegans* at the effective dose of 2.86  $\mu\text{g}/\text{ml}$ . In contrast, the effective anthelmintic plasma concentrations of closantel in sheep and cattle are  $\sim 50 \mu\text{g}/\text{ml}$  [73]. As stated above, closantel is thought to act as an uncoupler of mitochondrial oxidative phosphorylation, similar to other salicylanilides. It is possible that at the relatively low concentration at which it cures *C. elegans* of an MRSA infection, closantel may not completely disrupt mitochondrial oxidative phosphorylation. In fact, the low concentrations of closantel may be having an entirely opposite effect. Surprisingly, RNAi interference studies in *C. elegans* have shown that slightly reduced function of mitochondrial oxidative phosphorylation machinery extends lifespan in *C. elegans* [74]. As suggested by the RNAi experiments, it is possible that low concentrations of closantel could be having a hormetic lifespan-extending effect on the assay worms.

### Concluding Remarks

In this study, a robust *C. elegans*-based liquid infection assay was designed for testing both the anti-staphylococcal efficacy of compounds and their toxicity to a host in a single step. The ability of the assay to detect all of the clinically relevant antibiotics from a chemical library lends credence to the potency of the assay. Additionally, we report that the agent closantel identified in our screen has significant activity against MRSA and VRSA. Closantel is an attractive candidate for treatment of staphylococcal infections and we are further investigating its mechanism of action and clinical potential. Closantel is a prime example of the possibility of “repurposing” a drug already used in the clinic for other therapies. The assays described here could advance drug discovery using model organisms and decrease the need for mammalian testing.

### Acknowledgments

We thank N. Kirienko for sharing the R-programming language code which was used for analysing the high throughput screening data.

### Author Contributions

Conceived and designed the experiments: RR BBF YK EM. Performed the experiments: RR BBF EJ YK. Analyzed the data: RR BBF. Contributed reagents/materials/analysis tools: JLF AC. Wrote the paper: RR FMA EM.

### References

- Boucher HW, Corey GR (2008) Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5: S344–349.
- Jones RN (2003) Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997–2001). Semin Respir Crit Care Med 24: 121–134.
- Gottlieb GS, Fowler VG Jr, Kong LK, McClelland RS, Gopal AK, et al. (2000) Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a tertiary care facility. J Am Coll Surg 190: 50–57.
- Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, et al. (2007) Increasing incidence but decreasing in-hospital mortality of adult Staphylococ-

- cus aureus bacteraemia between 1981 and 2000. *Clin Microbiol Infect* 13: 257–263.
5. Feng Y, Chen CJ, Su LH, Hu S, Yu J, et al. (2008) Evolution and pathogenesis of *Staphylococcus aureus*: lessons learned from genotyping and comparative genomics. *FEMS Microbiol Rev* 32: 23–37.
  6. Lindsay JA (2010) Genomic variation and evolution of *Staphylococcus aureus*. *Int J Med Microbiol* 300: 98–103.
  7. Cuddy SM (2008) Methicillin-resistant *Staphylococcus aureus*: a new pandemic? *Plast Surg Nurs* 28: 168–169.
  8. Silver LL (2011) Challenges of antibacterial discovery. *Clin Microbiol Rev* 24: 71–109.
  9. Sifri CD, Begun J, Ausubel FM (2005) The worm has turned—microbial virulence modeled in *Caenorhabditis elegans*. *Trends Microbiol* 13: 119–127.
  10. Mylonakis E, Casadevall A, Ausubel FM (2007) Exploiting amoeboid and nonvertebrate animal model systems to study the virulence of human pathogenic fungi. *PLoS Pathog* 3: e101.
  11. Sifri CD, Begun J, Ausubel FM, Calderwood SB (2003) *Caenorhabditis elegans* as a model host for *Staphylococcus aureus* pathogenesis. *Infect Immun* 71: 2208–2217.
  12. Irazoqui JE, Troemel ER, Feinbaum RL, Luhachack LG, Cezairliyan BO, et al. (2010) Distinct pathogenesis and host responses during infection of *C. elegans* by *P. aeruginosa* and *S. aureus*. *PLoS Pathog* 6: e1000982.
  13. Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, et al. (2002) A conserved p38 MAP kinase pathway in *Caenorhabditis elegans* innate immunity. *Science* 297: 623–626.
  14. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, et al. (2002) Genome and virulence determinants of high virulence community-acquired MRSA. *Lancet* 359: 1819–1827.
  15. Fox PM, Lampen RJ, Stumpf KS, Archer GL, Climo MW (2006) Successful therapy of experimental endocarditis caused by vancomycin-resistant *Staphylococcus aureus* with a combination of vancomycin and beta-lactam antibiotics. *Antimicrob Agents Chemother* 50: 2951–2956.
  16. Campbell J, Singh AK, Santa Maria JP, Jr., Kim Y, Brown S, et al. (2011) Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem Biol* 6: 106–116.
  17. Tan MW, Mahajan-Miklos S, Ausubel FM (1999) Killing of *Caenorhabditis elegans* by *Pseudomonas aeruginosa* used to model mammalian bacterial pathogenesis. *Proc Natl Acad Sci U S A* 96: 715–720.
  18. Beanan MJ, Strome S (1992) Characterization of a germ-line proliferation mutation in *C. elegans*. *Development* 116: 755–766.
  19. Tanaka-Hino M, Sagasti A, Hisamoto N, Kawasaki M, Nakano S, et al. (2002) SEK-1 MAPKK mediates Ca<sup>2+</sup> signaling to determine neuronal asymmetric development in *Caenorhabditis elegans*. *EMBO Rep* 3: 56–62.
  20. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen* 4: 67–73.
  21. Fuchs S, Pane-Farre J, Kohler C, Hecker M, Engelmann S (2007) Anaerobic gene expression in *Staphylococcus aureus*. *J Bacteriol* 189: 4275–4289.
  22. Powell JR, Ausubel FM (2008) Models of *Caenorhabditis elegans* infection by bacterial and fungal pathogens. *Methods Mol Biol* 415: 403–427.
  23. Kametsky L, Jones TR, Fraser A, Bray MA, Logan DJ, et al. (2011) Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. *Bioinformatics* 27: 1179–1180.
  24. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, et al. (2009) High-throughput screen for novel antimicrobials using a whole animal infection model. *ACS Chem Biol* 4: 527–533.
  25. Jorgensen JH, Ferraro MJ (2009) Antimicrobial susceptibility testing: a review of general principles and contemporary practices. *Clin Infect Dis* 49: 1749–1755.
  26. Day SR, Moore CM, Kundzins JR, Sifri CD (2012) Community-associated and healthcare-associated methicillin-resistant *Staphylococcus aureus* virulence toward *Caenorhabditis elegans* compared. *Virulence* 3: 576–582.
  27. Yang J, Chen Z, Ching P, Shi Q, Li X (2013) An integrated microfluidic platform for evaluating in vivo antimicrobial activity of natural compounds using a whole-animal infection model. *Lab Chip* 13: 3373–3382.
  28. Begun J, Sifri CD, Goldman S, Calderwood SB, Ausubel FM (2005) *Staphylococcus aureus* virulence factors identified by using a high-throughput *Caenorhabditis elegans*-killing model. *Infect Immun* 73: 872–877.
  29. Sifri CD, Baresch-Bernal A, Calderwood SB, von Eiff C (2006) Virulence of *Staphylococcus aureus* small colony variants in the *Caenorhabditis elegans* infection model. *Infect Immun* 74: 1091–1096.
  30. Wu K, Simor AE, Vearncombe M, McClure JA, Zhang K (2012) A *Caenorhabditis elegans* host model correlates with invasive disease caused by *Staphylococcus aureus* recovered during an outbreak in neonatal intensive care. *Can J Infect Dis Med Microbiol* 23: 130–134.
  31. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, et al. (2001) A simple model host for identifying Gram-positive virulence factors. *Proc Natl Acad Sci U S A* 98: 10892–10897.
  32. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, et al. (2006) Identification of novel antimicrobials using a live-animal infection model. *Proc Natl Acad Sci U S A* 103: 10414–10419.
  33. Kirienko NV, Kirienko DR, Larkins-Ford J, Wahlby C, Ruvkun G, et al. (2013) *Pseudomonas aeruginosa* disrupts *Caenorhabditis elegans* iron homeostasis, causing a hypoxic response and death. *Cell Host Microbe* 13: 406–416.
  34. Van Voorhies WA, Ward S (2000) Broad oxygen tolerance in the nematode *Caenorhabditis elegans*. *J Exp Biol* 203: 2467–2478.
  35. Suzuki T, Campbell J, Kim Y, Swoboda JG, Mylonakis E, et al. (2012) Wall teichoic acid protects *Staphylococcus aureus* from inhibition by Congo red and other dyes. *J Antimicrob Chemother* 67: 2143–2151.
  36. Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, et al. (2012) Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids. *Proc Natl Acad Sci U S A* 109: 18909–18914.
  37. Kielhofner MA (1990) Trimethoprim- sulfamethoxazole: pharmacokinetics, clinical uses, and adverse reactions. *Tex Heart Inst J* 17: 86–93.
  38. Mulazimoglu L, Drenning SD, Muder RR (1996) Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 40: 1534–1535.
  39. Hall WH, Opfer BJ, Gerding DN (1980) Comparative activities of the oxo-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. *Antimicrob Agents Chemother* 17: 273–279.
  40. Isnansetyo A, Horikawa M, Kamei Y (2001) In vitro anti-methicillin-resistant *Staphylococcus aureus* activity of 2,4-diacetylphloroglucinol produced by *Pseudomonas* sp. AMSN isolated from a marine alga. *J Antimicrob Chemother* 47: 724–725.
  41. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, et al. (1999) Comparative activities of cinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones lincosamide, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible *Staphylococcus aureus* strains. *Antimicrob Agents Chemother* 43: 421–423.
  42. Daum RS (2007) Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant *Staphylococcus aureus*. *N Engl J Med* 357: 380–390.
  43. Schito GC, Debbia EA, Pesce A (1996) Susceptibility of respiratory strains of *Staphylococcus aureus* to fifteen antibiotics: results of a collaborative surveillance study (1992–1993). The Alexander Project Collaborative Group. *J Antimicrob Chemother* 38 Suppl A: 97–106.
  44. Gilbert M, Boscia JA, Kobasa WD, Kaye D (1986) Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant *Staphylococcus aureus* endocarditis. *Antimicrob Agents Chemother* 29: 461–463.
  45. Rubin JE, Ball KR, Chirino-Trejo M (2011) Antimicrobial susceptibility of *Staphylococcus aureus* and *Staphylococcus pseudintermedius* isolated from various animals. *Can Vet J* 52: 153–157.
  46. Pohlod DJ, Saravolatz LD, Somerville MM (1988) In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones. *J Antimicrob Chemother* 22 Suppl D: 35–41.
  47. Al-Abdullah ES (2012) Gatifloxacin. *Profiles Drug Subst Excp Relat Methodol* 37: 183–243.
  48. Zuo GY, Li Y, Han J, Wang GC, Zhang YL, et al. (2012) Antibacterial and synergy of berberines with antibacterial agents against clinical multi-drug resistant isolates of methicillin-resistant *Staphylococcus aureus* (MRSA). *Molecules* 17: 10322–10330.
  49. Champney WS, Tober CL (2000) Specific inhibition of 50S ribosomal subunit formation in *Staphylococcus aureus* cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. *Curr Microbiol* 41: 126–135.
  50. Clarke AM, Zencov SJ (1989) Comparative in vitro activity of lomefloxacin, a new difluoroquinolone. *Eur J Clin Microbiol Infect Dis* 8: 164–168.
  51. Bishburg E, Bishburg K (2009) Minocycline—an old drug for a new century: emphasis on methicillin-resistant *Staphylococcus aureus* (MRSA) and *Acinetobacter baumannii*. *Int J Antimicrob Agents* 34: 395–401.
  52. Alba V, Urban E, Angeles Dominguez M, Nagy E, Nord CE, et al. (2009) In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. *Int J Antimicrob Agents* 33: 272–275.
  53. Walsh TJ, Hansen SL, Tatem BA, Auger F, Standiford HC (1985) Activity of novobiocin against methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 15: 435–440.
  54. Smith SM (1986) In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 29: 325–326.
  55. Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, et al. (1993) In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. *Antimicrob Agents Chemother* 37: 384–392.
  56. Sultana Y, Aqil M, Ali A (2005) Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation. *Acta Pharm* 55: 305–314.
  57. Saravu K, Mukhopadhyay C, Satyanarayanan V, Pai A, Komaranchath AS, et al. (2012) Successful treatment of right-sided native valve methicillin-resistant *Staphylococcus aureus* endocarditis and septicaemia with teicoplanin and rifampicin: a case report. *Scand J Infect Dis* 44: 544–547.
  58. Schmalreck AF, Kottmann I, Reiser A, Ruffer U, Schlenk R, et al. (1997) Susceptibility testing of macrolide and lincosamide antibiotics according to DIN guidelines. *Deutsches Institut für Normung. J Antimicrob Chemother* 40: 179–187.
  59. Qadri SM, Ueno Y, Postle G, Tullo D, San Pedro J (1993) Comparative activity of the new fluoroquinolone rifloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria. *Eur J Clin Microbiol Infect Dis* 12: 372–377.

60. Hoogkamp-Korstanje JA (1997) In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. *J Antimicrob Chemother* 40: 427–431.
61. Maple PA, Hamilton-Miller JM, Brumfitt W (1991) Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 35: 345–350.
62. Brun Y, Coulet M, Forey F, Fleurette J (1988) [In vitro activity of roxithromycin compared to 5 other macrolides against staphylococci]. *Pathol Biol (Paris)* 36: 613–618.
63. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 52: e18–55.
64. Martin RJ (1997) Modes of action of anthelmintic drugs. *Vet J* 154: 11–34.
65. Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, et al. (2010) Repositioning of an existing drug for the neglected tropical disease *Onchocerciasis*. *Proc Natl Acad Sci U S A* 107: 3424–3429.
66. Williamson RL, Metcalf RL (1967) Salicylanilides: a new group of active uncouplers of oxidative phosphorylation. *Science* 158: 1694–1695.
67. Hlasta DJ, Demers JP, Foleno BD, Fraga-Spano SA, Guan J, et al. (1998) Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel. *Bioorg Med Chem Lett* 8: 1923–1928.
68. Stock AM, Robinson VL, Goudreau PN (2000) Two-component signal transduction. *Annu Rev Biochem* 69: 183–215.
69. Beier D, Gross R (2006) Regulation of bacterial virulence by two-component systems. *Curr Opin Microbiol* 9: 143–152.
70. Stephenson K, Hoch JA (2002) Virulence- and antibiotic resistance-associated two-component signal transduction systems of Gram-positive pathogenic bacteria as targets for antimicrobial therapy. *Pharmacol Ther* 93: 293–305.
71. Barrett JF, Goldschmidt RM, Lawrence LE, Foleno B, Chen R, et al. (1998) Antibacterial agents that inhibit two-component signal transduction systems. *Proc Natl Acad Sci U S A* 95: 5317–5322.
72. Watanabe T, Okada A, Gotoh Y, Utsumi R (2008) Inhibitors targeting two-component signal transduction. *Adv Exp Med Biol* 631: 229–236.
73. Michiels M, Meuldermans W, Heykants J (1987) The metabolism and fate of closantel (Flukiver) in sheep and cattle. *Drug Metab Rev* 18: 235–251.
74. Hamilton B, Dong Y, Shindo M, Liu W, Odell I, et al. (2005) A systematic RNAi screen for longevity genes in *C. elegans*. *Genes Dev* 19: 1544–1555.